Expert Analysis

Highlight on Special Hepatic Issues and Populations

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Highlight on Special Hepatic Issues and Populations

Faculty:

Raymond T. Chung, MD
Mark S. Sulkowski, MD
Norah Terrault, MD, MPH

CME CREDIT INFORMATION

Release Date: 12/13/06

Expiration Date: 12/12/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss results of studies evaluating prognostic factors in patients with liver disease
Review the efficacy of various noninvasive markers of fibrosis in patients with HCV/HIV coinfection
Describe clinical data regarding treatment of patients with HCV/HIV coinfection
Review the latest clinical data on treatment strategies in the setting of liver transplantation
Review data on the use of hepatocellular downstaging in patients awaiting liver transplantation

Topics covered include:

DEBIO-025: A Novel Cyclophilin Antagonist in HCV/HIV Coinfection
PRESCO: Evaluating Dose and Duration of Therapy in HCV/HIV-Coinfected Patients
IL-6 Gene Polymorphisms in HIV/HCV-Coinfected Patients Receiving HCV Therapy
GBV-C Infection in HCV/HIV-Coinfected Patients
HCV/HIV Coinfection, HAART, and Liver Fibrosis
Noninvasive Liver Fibrosis Tests in HCV/HIV-Coinfected Patients
Survival and Prognostic Factors in HCV/HIV-Coinfected Liver Transplant Patients
Ribavirin Maintenance After Combination Peginterferon/Ribavirin in Liver Transplant Recipients With Recurrent HCV
Immunosuppression With Tacrolimus vs Cyclosporine After Transplant
Immunosuppressive Therapy in HCV Patients Following Liver Transplant
Immunosuppression With Rapamycin vs Calcineurin Inhibitors Following Transplant
Liver Transplant Complications: LDLT vs DDLT
Posttransplant Survival Rates and Downstaging of Hepatocellular Carcinoma

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.